Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Puretech Health plc (PRTC) Ordinary 1p

Sell:268.00p Buy:272.00p 0 Change: 4.50p (1.69%)
FTSE 250:0.82%
Market closed Prices as at close on 7 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:268.00p
Buy:272.00p
Change: 4.50p (1.69%)
Market closed Prices as at close on 7 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:268.00p
Buy:272.00p
Change: 4.50p (1.69%)
Market closed Prices as at close on 7 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PureTech Health PLC is a clinical stage biotechnology company. The Company is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.

Contact details

Address:
501 Boylston St Ste 6102
BOSTON
02116-3769
United States
Telephone:
+1 (0617) 4822333
Website:
puretechhealth.com/

Important dates

Future events
Interim results 27 August 2020 27/08/20
Past events
AGM 11 June 2020 11/06/20
Final results 09 April 2020 09/04/20
Interim results 27 August 2019 27/08/19

General stock information

EPIC:
PRTC
ISIN:
GB00BY2Z0H74
Market cap:
£771.25 million
Shares in issue:
285.65 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE 250,FTSE 350,FTSE All Share

Key personnel

  • Bharatt Chowrira
    President, Chief of Business and Strategy
  • Daphne Zohar
    Chief Executive Officer, Co-Founder, Director
  • Robert Langer
    Co-Founder, Non-Executive Director
  • Joep Muijrers
    Chief Financial Officer
  • Stephen Muniz
    Chief Operating Officer, Company Secretary, Director
  • Joseph Bolen
    Chief Scientific Officer
  • Eric Elenko
    Chief Innovation Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.